Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry

Abstract

To establish in a global setting the relationships between countries' socioeconomic status (SES), measured biological disease modifying antirheumatic drug (bDMARD)-usage and disease outcomes. To assess if prescription and reimbursement rules and generic access to medication relates to a countries' bDMARD-usage.